I work in the Gene and Cell Therapy industry actually Novartis is one of our clients. The challenges faced producing the results they need is always down to 3 limiting factors: money, research and experience. Also, at least in Europe I was under the impression that recombinant ex vivo cells to be re-inserted into a patient were engineered to contain a self-terminating switch to prevent GMO’s developing viral genes through mutations
Very nice! A specific targeted mode of therapy seems to be underway. I'm hoping the future will hold great promise for Immunotherapy and further development in its practical uses.
I work in the Gene and Cell Therapy industry actually Novartis is one of our clients. The challenges faced producing the results they need is always down to 3 limiting factors: money, research and experience. Also, at least in Europe I was under the impression that recombinant ex vivo cells to be re-inserted into a patient were engineered to contain a self-terminating switch to prevent GMO’s developing viral genes through mutations
Very nice! A specific targeted mode of therapy seems to be underway. I'm hoping the future will hold great promise for Immunotherapy and further development in its practical uses.
Hi i was just wondering "Would this CART -T cell therapy change patient's immunophenotype?"...in term of MRD!
Thanks for upload this video